



Minicircle-derived RNA interference as a novel gene-based anti-angiogenic therapy


PhD program in Biotechnology and Biosciences (BIOTECnico)

Cristiana da Silva Ulpiano (cristiana.ulpiano@tecnico.ulisboa.pt)

1 Motivation


- Gene-based therapies continue to advance, aiming at developing novel medicines for a broad range of diseases, including cancer.
- Tumour angiogenesis is one hallmark of cancer progression and depends on the interaction between different types of cells and many signalling molecules, such as vascular endothelial growth factor (VEGF).
- Blocking VEGF expression using RNA interference (RNAi) might be a promising strategy to slow down tumour growth.
- Expression vectors encoding short-hairpin RNAs (shRNAs) can silence gene expression *in vivo* as effectively as synthetic siRNAs.
- A promising delivery system are minicircles (MC), which are safe non-viral vectors capable of high levels of transgene expression.

We hypothesized that MC-derived RNAi molecules that target key players in the VEGF regulatory pathway could be a novel gene-based therapy for angiogenic disorders characterized by vascular overgrowth.




2 Materials and Methods

- E. coli* BW2P was used for the production and *in vivo* recombination of the parental plasmid (PP) into the miniplasmid (MP) and MC vector.




- Cell harvesting and plasmid purification (HiSpeed® Plasmid Maxi Kit Qiagen).




- Digestion with Nb.BbvCI: nick one of the MP strands and of the non-recombined PP.



- Multimodal chromatography: separation of the supercoiled (sc) MC from open-circular (oc) species in the mixture by increasing NaCl concentration.





- Human bone marrow-derived mesenchymal stromal cells (MSC) and human umbilical vein endothelial cells (HUVEC) were transfected with sc MCs and synthetic siRNAs targeting VEGF regulatory pathway molecules using microporation.




3 Results and Discussion

Production and purification of shRNA-expressing minicircles





- Nb.BbvCI digestion readily converted the sc MP into the corresponding oc form, which allowed the isolation of the sc MC by multimodal chromatography.

Evaluation of the therapeutic potential of shRNA-expressing MC



- RT-qPCR results revealed that the silencing effect of MC-shVEGF is stronger after 48h (KD=71%), decreasing in the following timepoints. This result was expected since the peak of expression of the MC is reached 2 days post-transfection.



- A preliminary experience under hypoxic conditions (i.e. 2% O₂) showed that MC-shHIF1 α induced a KD of 73% and 18% of HIF-1 α -mRNA and VEGF-mRNA 48h post-transfection, respectively.
- A preliminary experience of microporation of HUVEC indicated that MC-shVEGFR2 induced a KD of 37% after 48h.

4 Conclusions and Future Perspectives

This study provides important insights regarding the implementation of an MC-derived RNAi-based system that targets pro-angiogenic molecules, aiming at slowing down tumour angiogenesis.

Future studies:

- Further assessment of MC-shHIF1 α and MC-shVEGFR2 silencing potential, by optimization of MC quantity and timepoints post-transfection.
- Evaluation of the MC-induced silencing at the protein level.
- Evaluation of the effect of MC silencing on the pro-angiogenic potential of the transfected cells by performing *in vitro* functional angiogenesis assays.

ACKNOWLEDGMENTS: This work is financed by national funds from FCT - Fundação para a Ciência e a Tecnologia, I.P., in the scope of the project UIDB/04565/2020 and UIDP/04565/2020 of the Research Unit Institute for Bioengineering and Biosciences - iBB and the project LA/P/O140/2020 of the Associate Laboratory Institute for Health and Bioeconomy - i4HB. C. Ulpiano acknowledges FCT for the PhD grant PD/BD/150336/2019.